Exonavis is developing a unique production process from cultivation to ready-to-use-dose, using state-of-the-art bioreactors and isolation machinery.

Exonavis has successfully achieved a robust exosome production ability, as well as the characterization protocol of exosomes derived from Mesenchymal stem cells.

Exonavis has been established in January 2021 to commercialize Exosome technologies initially developed at Tel Aviv University. Besides the licensing agreement with Ramot, the commercial arm of Tel Aviv University, the company hold also an exclusive worldwide option to license technology under the agreement with Yissum.